A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers
- PMID: 35869354
- PMCID: PMC9402521
- DOI: 10.1007/s12325-022-02224-z
A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers
Abstract
Irritable bowel syndrome with diarrhea (IBS-D) is a chronic disorder of gut-brain interaction, characterized by recurrent abdominal pain in association with more frequent, loose stools. The pathophysiology of irritable bowel syndrome (IBS) includes disordered gut motility, alterations in gut microbiota, neural-hormonal system abnormalities, immune reactivity, and visceral hypersensitivity. Timely diagnosis of IBS-D can be achieved easily using clinical criteria. Formal IBS diagnosis is important for optimizing treatment and patient outcomes and facilitating patient access to appropriate educational resources. Yet, given the symptom overlap with other gastrointestinal conditions, diagnosis of IBS-D often is perceived to be challenging. Treatment of IBS includes both nonpharmacologic and pharmacologic options. Rifaximin, alosetron, and eluxadoline are effective treatments indicated for IBS-D, but have limited availability internationally. Dietary approaches may also be indicated for certain patients with IBS-D. Psychological interventions may be effective in treating abdominal pain alone and global symptoms in IBS. We describe use of these diverse therapies and provide an overview to facilitate the primary care provider's approach to distinguishing IBS-D from other conditions with symptom overlap.
Keywords: Abdominal pain; Bloating; Diagnosis; Diarrhea; Gastroenterology; Internal medicine; Irritable bowel syndrome; Primary health care; Therapeutics.
© 2022. The Author(s).
Figures
Similar articles
-
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.Adv Ther. 2020 Jan;37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9. Adv Ther. 2020. PMID: 31707713 Review.
-
Journal of Clinical Gastroenterology Lectureship Dubai 2022 : Management of Irritable Bowel Syndrome With Diarrhea.J Clin Gastroenterol. 2024 Mar 1;58(3):221-231. doi: 10.1097/MCG.0000000000001964. J Clin Gastroenterol. 2024. PMID: 38227850
-
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Pharmacotherapy. 2016. PMID: 26971716 Review.
-
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8. Expert Opin Pharmacother. 2016. PMID: 26559529 Review.
-
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Expert Rev Gastroenterol Hepatol. 2016;10(4):431-42. doi: 10.1586/17474124.2016.1140571. Epub 2016 Mar 1. Expert Rev Gastroenterol Hepatol. 2016. PMID: 26753693 Review.
Cited by
-
Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review.World J Gastroenterol. 2023 Jun 7;29(21):3241-3256. doi: 10.3748/wjg.v29.i21.3241. World J Gastroenterol. 2023. PMID: 37377581 Free PMC article. Review.
-
Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome.World J Gastroenterol. 2023 Jul 28;29(28):4451-4465. doi: 10.3748/wjg.v29.i28.4451. World J Gastroenterol. 2023. PMID: 37576702 Free PMC article. Clinical Trial.
-
A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome.Clin Drug Investig. 2024 Nov;44(11):839-847. doi: 10.1007/s40261-024-01403-w. Epub 2024 Oct 30. Clin Drug Investig. 2024. PMID: 39476291
-
A preliminary study of the association between Blastocystis and quantification of selected yeasts in IBD and IBS patients.Front Med (Lausanne). 2025 Feb 13;12:1514587. doi: 10.3389/fmed.2025.1514587. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40018349 Free PMC article.
-
Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.Adv Ther. 2024 Jun;41(6):2253-2266. doi: 10.1007/s12325-024-02832-x. Epub 2024 Apr 15. Adv Ther. 2024. PMID: 38619720 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources